Methodological Issues and Controversies in COVID-19 Coagulopathy: A Tale of Two Storms

Samuel A Berkman¹ and Victor F Tapson²

Abstract
Venous thromboembolism, occlusion of dialysis catheters, circuit thrombosis in ECMO devices, all in the face of prophylactic and sometimes even therapeutic anti-coagulation, are frequent features of COVID-19 coagulopathy. The trials available to guide clinicians are methodologically limited. There are several unresolved controversies including 1) Should all hospitalized patients with COVID-19 receive prophylactic anti-coagulation? 2) Which patients should have their dosage escalated to intermediate dose? 3) Which patients should be considered for full-dose anti-coagulation even without a measurable thromboembolic event and how should that anti-coagulation be monitored? 4) Should patients receive post-discharge anti-coagulation? 5) What thrombotic issues are related to the various medications being used to treat this coagulopathy? 6) Is anti-phospholipid anti-body part of this syndrome? 7) How do the different treatments for this disease impact the coagulation issues? The aims of this article are to explore these questions and interpret the available data based on the current evidence.

Introduction
We are currently in the throes of a pandemic with a significant death toll without clear therapeutic options. Turning to the literature for guidance is fraught with obstacles. There hasn’t been time to accumulate data with any significant precision. In addition to being underpowered, preliminary trials are nonrandomized, frequently from a single institution, and observational or laboratory based.

The relationship between viral infection and thrombosis, including coronavirus severe acute respiratory syndrome (SARS) and Middle Eastern respiratory syndrome (MERS) is not new but the scope of the COVID-19 pandemic has brought this concern to the forefront of clinical practice. In the setting of COVID, severely ill patients are frequently receiving multiple treatments and it is hard to unravel the potential benefit of any individual treatment.¹⁻⁵

Consequently, with respect to sorting out the optimal management of thrombosis and hypercoagulability, we are in large part dependent upon expert guidelines, which while helpful, may be conflicting and even absent regarding certain issues. Furthermore, some of these guidelines are extrapolated from populations other than COVID patients. (Table 1) Clinicians are struggling with numerous dilemmas unique to the prothrombotic characteristics of this disease.

Coagulation and Lung Injury Prior to COVID
Clinical data to date support that COVID-19 is associated with a prothrombotic state that is not simply explained by an influx of more critically ill individuals. A key aspect of the pathophysiology of acute lung injury and adult respiratory distress syndrome (ARDS) in the “pre-COVID-19 era” is the presence of fibrin-rich exudative hyaline membranes which develop in lung alveoli due to activation of coagulation and inhibition of fibrinolysis; i.e., a balance that is shifted in a procoagulant / antifibrinolytic direction favoring fibrin formation.⁶ Despite extensive research in this area, the direct effects of activation of coagulation on inflammatory pathways and perpetuation of lung injury are not still well understood.⁷ While clinical studies targeting the coagulation cascade in patients with, or at risk of lung injury have been interesting and promising, there have been no major breakthroughs impacting on mortality in this population prior to the COVID pandemic.⁸

Frequency of Thromboembolic Events In COVID-19 Patients
Marked elevation of both markers of hypercoagulability and inflammation combine to make COVID a very hypercoagulable state.

¹ Department of Medicine
² Cedars-Sinai Medical Center Los Angeles, CA, USA

Corresponding Author:
Samuel A. Berkman, MD, FACP 9001 Wilshire Blvd, Suite 200 Beverly Hills, CA 90211, USA.
Email: sberkman@ucla.edu
| Table 1. Guidelines On Anticoagulation Management Form Various Societies. |
|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| ISTH\textsuperscript{17} | ASH\textsuperscript{18} | AC FORUM\textsuperscript{19} | Mass General Hospital\textsuperscript{63} | American Venous Forum\textsuperscript{64} | Joint ISTH, NATF, ESVM, IUA \textsuperscript{66} |
| **DVT PROPHYLAXIS HOSPITAL** | All Covid patients without contraindications | All patients LMWH or Fondaparinux. No recommendations on dose escalations recommend randomized trials | All Covid patients without contraindications | LMWH favored for all patients without contraindications | Double dose if Caprini score over 8 or if BMI over 35 |
| **DVT Prophylaxis post discharge** | Not specifically addressed | Decide based upon status at discharge | Not directly addressed | Not specifically addressed | Risk stratification |
| **DVT or PE** | Full dose anticoagulation 3 months. Switch from heparin preparation to oral med post discharge | Full dose LMWH or UFH 3 months Switch to po med post d/c | LMWH over UFH 3 months Switch to po med post d/c | LMWH over UFH 3 months Switch to po med post d/c | 3 Months UFH or LMWH Switch to oral anticoagulant post d/c |
| **Cytokine and thrombotic storm no measurable DVT or PE** | Full dose heparin not addressed Consider experimental therapies | Full dose heparin not addressed | Not specifically addressed | Don’t recommend Full dose AC in absence of DVT or PE. If high clinical likelihood of DVT and/or PE and testing impossible only then consider therapeutic AC | For D Dimer over 3 full doses recheck Ultrasound at 2 weeks. If no DVT at 6 wks give prophylaxis dose for 3 months, if DVT or PE 3 Months therapeutic dose |
| **Other Details** | If D Dimer markedly raised admit even if no other indications | DOACs better than VKAs post discharge particularly if isolation desired | Use anti Xa levels for monitoring Do not recommend TPA | Do not recommend TPA Venous duplex only if it will change management | LMWH heparin preferred for AC but heparin for impending procedures. Numerous Covid drugs have interactions with anti platelet meds |

\textsuperscript{17} ISTH- International society of thrombosis and haemostasis \\
\textsuperscript{18} ASH- American Society of Hematology \\
\textsuperscript{19} AC Forum – Anticoagulation Forum \\
\textsuperscript{63} MGH Massachusetts General hospital Hematology \\
\textsuperscript{64} NATF- North American Thrombosis Forum \\
\textsuperscript{66} ESVM- European Society of Vascular Medicine \\
\textsuperscript{66} IUA International Union of Angelology
Table 2. Mechanism of antithrombotic and anticytokine storm activity mediated by COVID treatment.

| Treatment                     | Mechanism of antithrombotic effect                                                                 |
|-------------------------------|---------------------------------------------------------------------------------------------------|
| Heparin (LMWH or UFH)         | Anti-Xa and anti-IIa with secondary inhibition of platelet activation by protease-activated receptors, with secondary inhibition of generation of cytokines, including IL1, IL6, and TNF alpha from monocytes and macrophages and neutrophils (NETS) |
| Fondaparinux                  | Anti-Xa with secondary inhibition of platelet activation by PARs, with secondary inhibition of generation of cytokines including IL1, IL6, and TNF alpha from monocytes and macrophages and neutrophils (NETS) |
| Direct oral anticoagulants    | Anti-Xa and anti-IIa with secondary inhibition of platelet activation by PARs, with inhibition of generation of cytokines including IL1, IL6, and TNF alpha from monocytes and macrophages and neutrophils (NETS) (less anti-inflammatory than heparins) |
| Hydroxychloroquine Remdesivir | Anti CD4, antiplatelet gp Iib-IIa, protects Annexin shield, moderate inhibition of P-gp (but not of CYP3A4) |
| Tocilizumab                   | Anti-IL6, clinically relevant drug interactions not anticipated |
| Convalescent plasma           | Antibody neutralizes virus preventing generation of thrombotic and cytokine storm |

Abbreviations: Anti-IIa, activated factor II; anti-Xa, activated factor X; CD40, CD40 ligand; IL1, interleukin 1; IL6, interleukin 6; LMWH, low molecular weight heparin; PAR, protease activated receptors on platelets and endothelium; TNF, tumor necrosis factor alpha; UFH, unfractionated heparin; NETS, neutrophil extracellular traps.

In contrast to other sources of hypercoagulability and inflammation, the lung seems to be the engine of both pathways. Venous thromboembolism is an inflammatory disease and evidence is accumulating that the factors influencing the development of VTE are not restricted to the coagulation system. The immune system is also closely involved with the formation and resolution of thrombosis. Surgery, obesity, sepsis, systemic infection, cancer, inflammatory bowel disease, and lupus are VTE risk factors that may modulate thrombosis through inflammatory mediators. It is thus, easy to speculate how the surge in inflammation seen in COVID-19, with dramatic elevations in C-reactive protein (CRP), interleukin-6 (IL-6), and ferritin, must somehow stimulate clot formation.

Furthermore, meta-analytic data have demonstrated that less severely ill COVID-19 patients have lower levels of CRP, IL-6, and serum ferritin, than more severely ill patients, and survivors have lower IL-6 levels than those who die. As with coagulation parameters, there is no clear consensus for how to address markedly elevated inflammatory markers in these patients; understanding the role of inflammation in the aforementioned clinical situations, and in COVID-19, may not only help determine the optimal management but may also aid in the development of future preventive strategies.

In view of the above, should one use either prophylactic or intermediate dose anti-coagulation prophylaxis in every hospitalized COVID patient without bleeding contraindications? This controversy is fueled by a prospective nonrandomized trial of 183 consecutive hospitalized novel coronavirus pneumonia patients from China strongly correlating mortality with degree of D-dimer elevation and presence of disseminated intravascular coagulation (DIC). Furthermore, a Dutch study of 184 ICU patients with COVID pneumonia showed a 31% incidence of thrombotic complications in the face of prophylactic dose anti-coagulation. A third single center retrospective trial of patients with severe coronavirus pneumonia showed a 25% incidence of DVT in ICU patients. A fourth Italian trial showed a 7.7% rate of thrombotic events with a cumulative rate of 21%. More than half of these events occurred during the first 24 hours of hospitalization.

All four of these trials were small, non-randomized, single institutional trials. Despite these limitations, several societies including ASH and ISTH and the Anti-coagulation Forum have recommended at least prophylactic dose anti-coagulation for any hospitalized COVID patient without excessive bleeding risk or other contraindications. (Table 1)

Who Might Be a Candidate For Prophylactic Dose Escalation In The Hospital?

The question also arises as to which patient should be switched from prophylactic to intermediate-dose prophylactic anti-coagulation mainly with low molecular weight heparin. Unfortunately no studies have been completed that answer this question. A study in two French intensive care units looked at 26 consecutive patients with severe COVID, 31% of whom were treated with prophylactic anti-coagulation and 69% with therapeutic anti-coagulation and the overall rate of VTE was 69%. This study was retrospective and had small numbers of patients, nonetheless the results are consistent with other reports revealing very high incidence of thrombosis in hospitalized COVID patients. In addition to this trial and the Netherlands trial another study from France showed a very high risk of thrombosis on anti-coagulation in patients with severe COVID-19. This multicenter prospective cohort study of 150 COVID patients in four intensive care units observed 64 thrombotic events occurring in 150 patients. Of these, 80% were on prophylactic dose anti-coagulation and 20% were on a therapeutic dose and 28 of 29 patients receiving renal replacement therapy developed...
circuit thrombosis while three developed extracorporeal membrane oxygenation (ECMO) occlusions.

In view of the above mentioned studies, some of the guidelines recommend increasing prophylactic dose anti-coagulation to intermediate dose in ICU patients and possibly stepping down the dosage when one return to the medical floor. Basing dose increase upon a markedly elevated D-dimer level has also been proposed. The ISTH document suggests only “prophylaxis” but does not make dosing recommendations. The ASH document states that “prophylactic dose anti-coagulation is recommended for all hospitalized COVID-19 patients” and that “therapeutic anti-coagulation is not required unless another indication for therapeutic anti-coagulation is documented.” The latter is increasingly debated.

Because most patients hospitalized with severe medical illness will have an elevated D-dimer, in the past that marker, in and of itself, has not been viewed as a stand-alone indication for initial anti-coagulation prescribing of any dosage. However in this setting, this point may be debatable since here the D-dimer has been associated with mortality, and may also be a biomarker for cytokine storm and not just thromboembolism. Marked elevation of inflammatory markers such as C-reactive protein (CRP), ferritin, and interleukin-6, and thrombotic markers including D-dimer, fibrinogen, and protime prolongation may be useful as weighted markers for constructing risk assessment models for escalating prophylactic dosage of anti-coagulants, although at present no strong evidence base exists.

The Severely Ill or Deteriorating Patient

A related issue is what is the best way to treat COVID coagulopathy when a patient’s status deteriorates? Deterioration may be connected to a battle between the immune system and the spike proteins of the COVID virus which bind to ACE2 receptors in the alveolar walls of the lung. (Figure 1) The damage to the lung which ensues is both alveolar and vascular and is due both to toxicity of virus plus binding of anti-body to the endothelium simultaneously activating the clotting cascade and the inflammatory pathway with major cytokine generation.

This situation leads to pulmonary microthrombosis (documented in autopsy studies) rendering oxygen exchange more difficult and more widespread cytokine storm.
DIC. This particular pathologic finding to this degree has not been reported in other causes of thrombotic or cytokine storm, making this a unique coagulopathy. Specifically an autopsy study from Germany showed that the lungs of patients who died from COVID-19 pneumonia had 9 times as many alveolar capillary microthrombi in comparison to those who died from ARDS secondary to influenza and 2.7 times as much new vessel growth as those who died from influenza associated ARDS.22

The coagulopathy has features both of thrombotic storm,23,24 and cytokine storm.25 The thrombotic storm component bears some similarities to heparin-induced thrombocytopenia based upon the high thrombosis rate, the mild thrombocytopenia as well as the low incidence of bleeding despite DIC. COVID patients who develop DIC have a much higher mortality than those who do not, but not from bleeding.12,13,14 Thrombotic storm is frequently triggered by surgery or infection and the spectrum includes catastrophic anti-phospholipid syndrome, heparin-induced thrombocytopenia, macrovascular TTP, malignancy and severe DIC.25

Patients with thrombotic storm frequently have simultaneous large- and small- vessel thromboses in several beds, both arterial and venous. They can develop multiple thromboses within a very short period of time. By contrast, with cytokine storm, while large vessel thromboses are common, early vascular collapse and multiple organ system failure are more common than with thrombotic storm alone. It is hard to pinpoint exactly which of these two systems is contributing more to the large and small vessel thrombosis in COVID, but they seem to be inextricably intertwined. The combination of the two storms makes this a unique coagulopathy.

Full-Dose Anti-coagulation

Conflicting guidelines have been released regarding escalation to full-dose heparinization with either unfractionated or low molecular weight heparin (LMWH) in patients who are deteriorating on either low- or intermediate-dose prophylaxis, particularly those on ventilators, without documented diagnoses of pulmonary embolism (PE) or deep venous thrombosis (DVT) (Table one) This strategy is reinforced by the low incidence of bleeding observed in COVID patients compared with other causes of DIC such as obstetrical ones.13-15 The ISTH document states that “if there is worsening of these (coagulation) parameters, more aggressive critical care support is warranted and consideration should be given for more ‘experimental’ therapies and blood product support as appropriate.”17 However, it isn’t clear what measures are actually recommended.

There are no randomized trials that pertain to this situation; however a retrospective study looked at 2,773 patients with laboratory-confirmed COVID. Of those who required mechanical ventilation, there was an in-hospital mortality of 29.1% with a median survival of 21 days for those treated with full dose anti-coagulation as compared to 62.7% with a median survival of 9 days in people who did not receive treatment dose anti-coagulation.26

One of the problems interpreting this study is that anyone who received escalation to full-dose anti-coagulation would almost certainly already have been placed on more aggressive therapy including perhaps hydroxychloroquine, remdesivir, another anti-viral drug, an anti-interleukin-6 antagonist and/or convalescent plasma. It would therefore, be challenging to ferret out how much the full-dose anti-coagulation, or any other single modality, would be contributing to any positive outcome. While the major bleeding in trials involving COVID patients thus far appears to be low, full-dose anti-coagulation in such ill patients is not benign. The majority, but not all of the guidelines, have suggested that whether a person is placed on full-dose anti-coagulation because of a definitive thromboembolic event or because they are felt to be deteriorating from a combined thrombotic and cytokine storm, the full therapeutic dose should be continued for at least 3 months after hospital discharge. (Table 1)

Post-Discharge Prophylaxis?

Practitioners also want to know if the combination of the very elevated biomarkers of hypercoagulability and inflammation warrant continuation of anti-coagulation prophylaxis post discharge in view of the lengthy hospital stays with prolonged immobilization in many COVID patients. With respect to this issue, clinicians may be directly or indirectly swayed by the strongly negative recommendations from the 2018 guidelines from the American Society of Hematology (ASH) regarding post-hospital discharge prophylaxis in high risk hospital medical patients.27

The ASH could not possibly have foreseen the uniqueness of the coagulopathy associated with this new disease in generating their 2018 recommendations, particularly the component of cytokine storm with the lung acting distinctively as the engine. In generating their guidelines, they also elected to discount the mortality potential of asymptomatic proximal venous thrombosis observed in the MAGELLAN26 and APEX29 trials citing that a meta-analysis of 26 randomized studies did not show an increased risk of mortality in asymptomatic proximal venous thrombosis.27

However, since 2018, post hoc analyses of MAGELLAN and APEX (both highly powered randomized trials) have reported increased mortality associated with asymptomatic proximal venous thrombosis.28,29 Unfortunately none of these trials, which looked at asymptomatic proximal venous thrombosis as an endpoint, reported ultrasound appearance as to whether the clots were acute, subacute or chronic.

Immobilization is a potent risk factor for the development of DVT in hospitalized medical patients and COVID patients. These patients, both requiring and not requiring mechanical ventilation, tend to be immobilized for longer than those in previous studies of DVT prophylaxis post-discharge such as MAGELLAN30, APEX31 or MARINER.32 At this time, very few data are available about post-discharge VTE in COVID. Nonetheless, to assume that the effects of the striking elevations in D-dimer, CRP and interleukin-6 regularly observed in
COVID patients will suddenly vanish upon the patient’s departing the hospital is questionable. This point is particularly relevant, since several randomized trials have shown that two of three thromboembolic events associated with hospitalization in medical patients occur in the first 30 days post discharge.\(^3\)

ASH constructed their recommendation by generating a meta-analysis of three trials - ADOPT\(^3\), MAGELLAN\(^3\), and APEX.\(^3\) ADOPT and MAGELLAN were initially considered failed trials and APEX was successful only if one includes asymptomatic proximal venous thrombosis as a significant endpoint. Unless a physician can say that they would not prescribe anti-coagulation for an asymptomatic proximal venous thrombosis in a COVID patient, it would seem inappropriate to issue a strong negative guideline on post-hospital discharge prophylaxis in these patients given their unique hypercoagulable predispositions. ASH and others will hopefully develop new guidelines specifically with respect to COVID patients. The risk of major bleeding on low-dose DOAC prophylaxis would appear to be low when considering the available data from\(^3\) MARINER,\(^2\) as well as the EINSTEIN CHOICE\(^4\) and AMPLIFY-EXTEND trials.\(^3\)

**Effect of Anti-COVID-19 Medications on Thromboembolism**

With respect to the cytokine storm component of this unique coagulopathy, the same scenario has been described extensively in patients receiving chimeric antigen receptor (CAR)-T treatment for lymphoma or leukemia.\(^4\) In this condition, one of the most important cytokines which gets activated is interleukin-6. Two trials with monoclonal anti-bodies against interleukin-6 in COVID patients have shown positive results; one in a Chinese trial and another from Qatar.\(^2,^3\)

**Tocilizumab** Tocilizumab is a monoclonal anti-body directed against interleukin-6 which has shown good activity against cytokine storm in CAR-T cell treatments.\(^2\) In a Chinese trial of 21 COVID patients who either were on ventilators or considered seriously ill with COVID pneumonia, all survived after receiving one dose of tocilizumab intravenously. Patients also had significant rapid improvements in blood oxygen, with plummeting levels of inflammatory cytokines and symptom resolution.\(^2\) The patients were also receiving other anti COVID therapies including Lopinavir, methylprednisolone, othersymptom relievers, and oxygen therapy.

In the Qatar trial, tocilizumab was given to 25 patients with severe COVID infection.\(^3\) 84% of the patients were on mechanical ventilation on day 1 and by day 14 only 28% were on ventilators and only 3 of 25 died. C-reactive protein plunged from 193 on day 1 to 7.9 on day 7. Patients were also getting hydroxychloroquine and azathioine, alpha interferon and lopinavir/ritonavir. No data were presented in the two studies about thrombotic events and overall interpretation is difficult in these nonrandomized uncontrolled tocilizumab studies.\(^2,^3\)

**Hydroxychloroquine** With respect to therapies for COVID, hydroxychloroquine has been widely used in hospitalized COVID patients based on in vitro studies showing inhibition of viral activity\(^4\) and based on an underpowered French clinical study discussed below.\(^5\) What has not been as widely emphasized during this pandemic is that this drug has been shown in several studies to lower platelet C4d levels, a strong predisposing marker for thrombosis in lupus patients, which sits at the border of the clotting and complement pathways.\(^4,^6\) Hydroxychloroquine also inhibits platelet induced GPIIb/IIIa expression as well as protecting the annexin shield from
breakdown by anti-phospholipid anti-bodies. In a prospective, nonrandomized trial the addition of hydroxychloroquine to anti-coagulation reduced the risk of recurrent thrombosis in (non-COVID) lupus patients from 20% to zero.

The studies of the anti-viral effects of hydroxychloroquine do not give such impressive results. A French trial studied 36 hospitalized COVID patients, 22 with upper respiratory symptoms, 8 with lower respiratory symptoms and six who were asymptomatic. Of these patients, 26 received hydroxychloroquine 200 mg three times a day. There was a 70% reduction in viral load in the nasopharynx at six days compared to a nonrandomized control group.

Because of the small number of patients, this study would have very wide confidence intervals and lacks precision. In addition, it did not measure clinical outcomes such as thrombosis, rather a surrogate result of viral load in the nose and throat, a measure not necessarily correlated with clinical outcomes. Furthermore, groups were not randomized and several patients assigned to the intervention group who refused to take the drug joined the control group, causing unbalanced groups and potential bias.

One positive point about the study is the authors did have the foresight to exclude patients with QT prolongation or eye disease, a point which bears emphasis. Finally, the patients were all hospitalized, although it’s unclear why the six asymptomatic patients were hospitalized to begin with.

A second trial done by the Veterans Administration in the United States evaluating 368 patients revealed no benefit from this drug either in combination with azithromycin or by itself in COVID positive patients, in fact there was an increased mortality. The studies of the anti-viral effects of hydroxychloroquine do not give such impressive results. A French trial studied 36 hospitalized COVID patients, 22 with upper respiratory symptoms, 8 with lower respiratory symptoms and six who were asymptomatic. Of these patients, 26 received hydroxychloroquine 200 mg three times a day. There was a 70% reduction in viral load in the nasopharynx at six days compared to a nonrandomized control group.

The endpoint was either intubation or death and there was no difference between the groups. The mean follow-up was 22 days. There were no secondary end points, consequently no data on incidence of thromboembolic events in either group. In view of such questionable impact on survival and respiratory symptomatology, the question arises as to whether the repeatedely documented anti-thrombotic actions of this drug noted in systemic lupus are convincing enough to justify its use to supplement anti-coagulation and other measures to combat thrombosis in COVID. Nonetheless, the FDA granted emergency use authorization for this drug in COVID, but rescinded it after a randomized trial of 821 healthy adults showed no benefit compared to a placebo group in development of COVID infection after receiving hydroxychloroquine within four days of COVID exposure.

**Anti-viral Therapy**

**Remdesivir** Remdesivir is also frequently prescribed to patients with severe COVID coagulopathy. It becomes incorporated into the viral genome and is able to act as a chain terminator. It has improved disease outcomes and reduced viral loads in SAR-CoV infected mice and in MERS-CoV infected mice. A double-blind randomized trial in China involving 237 patients with COVID pneumonia did not show remdesivir to be associated with any clinical benefit. The more highly powered NIAID ACTT1 trial, trial involving 1059 patients showed that the median time to recovery was 31% faster for recipients of remdesivir 11 days versus 15 days. There was a trend toward mortality benefit (p = 0.059) but it appears that the results were good enough that the U.S. not only granted this drug emergency use authorization, but cited it as the standard of care.

The recently completed phase II ACTT2 trial, placed all patients on on remdesivir and them randomized to baricitinib (a JAK 1 / JAK 2 inhibitor) or placebo, and results are being analyzed. While these trials did not look at the specific impact of remdesivir on thrombosis, it is feasible that an anti-thrombotic effect could be based on its direct anti-viral effect attenuating its toxicity on the alveoli and vascular endothelium in the lung. If this is indeed true, it would appear ideal to administer the drug early rather than after the cytokine storm has been generated, which may be akin to avoiding closing the barn door after the horse has been let out.

**Other Anti-viral Drugs**

Lopinavir / ritonavir a trial of 199 patients with confirmed SARS-Cov-2 infection underwent randomization. One group received standard of care which consisted of supplemental oxygen, noninvasive or invasive ventilation as needed, anti-biotic agents, vasopressor support, renal replacement therapy and ECMO, when needed. The treatment group received the entire regimen above plus lopinavir-ritonavir. There was no difference in mortality at 28 days or percentages of people with detectable viral RNA at various time points and there were no thrombotic events listed or measured in the outcomes.

**Convalescent Plasma**

Plasma infusions from people who have recovered may be helpful. A study looking at five patients with COVID pneumonia on ventilators who received plasma from recovered COVID patients showed that all of them recovered. There was also improvement in oxygenation and viral loads within a few days. There were no adverse effects. Because they were all on anti-viral drugs and methylprednisolone and there was no control group it’s difficult to know how much of the role the convalescent plasma played.

A second trial looked at ten patients with COVID which was characterized as severe; three were on ventilators. All recovered and CRP dropped from 55 to 8 ug/mL within three days. There were no adverse effects from the plasma specifically, no
thrombosis and no adverse renal effects. The patients were all on anti-viral therapy and steroids. If this treatment had any beneficial effect on thrombotic or cytokine storm, as with the monoclonal anti-bodytocilizumab, it may well have been in attenuating the effect of the virus on the binding to the ACE2 receptors and lessening endothelial and alveolar injury. It is still unknown whether these anti-bodies are neutralizing and protective in vivo; we need randomized trials. There were no comments on potential thrombosis attenuation in these trials.

Corticosteroids

Although corticosteroids were not very effective in SARS, MERS, influenza or community-acquired pneumonia, the RECOVERY trial, one of the few randomized trials in COVID to date, randomized 2,104 COVID patients to 6-10 days of dexamethasone in a dose of 6 mg once daily versus 4,321 with usual care. There was 17%, improvement in mortality overall and in a third of patients requiring mechanical ventilation as well as 20% in those on supplemental oxygen. However, the mortality of patients requiring mechanical ventilation was 40% and for those requiring supplemental O2 it was 25%. Importantly the trial, was neither blinded, nor placebo controlled, the comparator group was usual care, and the overall mortality was much higher than in many current hospital settings making it difficult to accept the results without more further study. There was no direct mention of an effect on thrombotic events nor did it clearly define usual care except to state that during the recovery period there was very little use of IL-6 inhibitors, anti-viral drugs, or hydroxychloroquine in either group.

Conclusions

In summary many critically ill COVID patients are now being treated with combinations of hydroxychloroquine, plasma infusions, remdesivir, or antagonists of interleukin-6. If one is getting multiple treatments, it may be challenging to discern to which component to attribute the benefit. Some of these treatments are very expensive and have significant toxicities and combinations can cause combined toxicities.

From a thrombosis point of view, full-dose anti-coagulation against thrombotic storm in concert with corticosteroids and/or interleukin-6 antagonists against cytokine storm could theoretically constitute a rational therapy against both entities in more critically ill patients, but based on very weak evidence. Randomized trials are underway. Remdesivir has been characterized as the new standard of care for COVID-19 pneumonia but is clearly not enough. While hydroxychloroquine may be a potent anti-thrombotic drug in inflammatory diseases like lupus, any potential effect on thrombosis has not specifically been teased out in COVID. Plasma therapy from recovered patients is another tool which probably works by directly antagonizing the virus preventing primary endothelial and alveolar injury and generation of cytokines and micro thrombosis and may be best used early. Dexamethasone has emerged as a therapeutic option based upon one of the few randomized trials available to date, but more data are needed.

There is convincing evidence from numerous studies that all hospitalized patients should receive at least prophylactic dose anti-coagulation. Whether to escalate to intermediate dose based on laboratory test results or movement to an ICU is controversial. However more and more studies are showing thrombosis in the face of prophylactic and even higher dose anti-coagulation. Post discharge anti-coagulation would seem to make sense in most cases given the high rate of thrombosis in hospitalized patients in the face of various dosages of anti-coagulation, the prolonged immobilization and very high markers of inflammation and thrombosis routinely seen in these patients. Additionally sick medical patients tend to develop the majority of clots post discharge. At this time there is a paucity of data regarding thrombosis as an endpoint in studies of various drug treatments of COVID.

We will need to know more about the neutralizing activity of anti-COVID anti-bodies generated either by the disease or by vaccination. Hopefully, the tremendous interest and ongoing research in this contagious and mortal disease will contribute to dramatic reductions in the incidence, morbidity and mortality. If one is going to get this virus they would certainly be better off getting a few years from now when some of these issues, particularly the optimal combinations of treatment are worked out.

Funding

Research funding has been paid to the institutions with which Victor Tapson is associated by Bayer, Bristol Myers Squibb, EKOS/BTG / Boston Scientific, Daiichi, Janssen, and Penumbra. He has been a consultant or on the advisory boards to Bayer, Bristol Myers Squibb, EKOS/BTG / Boston Scientific, Janssen, and Penumbra. He has been a speaker for Janssen. Samuel Berkman is a speaker for Janssen pharmaceuticals and Portola.

ORCID ID

Samuel A Berkman https://orcid.org/0000-0002-5610-0823

References

1. Bunce PE, High SM, Nadjafi M. Pandemic H1N1 influenza infection and vascular thrombosis. Clin Infect Dis 2011; 52: e14-7.
2. Avnon LS, Munteanu D, Smoliakov A, et al. Thromboembolic events in patients with severe pandemic influenza A/H1N1. Eur J Intern Med 2015; 26:596-8.
3. Chong PY, Chui P, Ling AE, et al. Analysis of deaths during the severe acute respiratory syndrome (SARS) epidemic in Singapore: challenges in determining a SARS diagnosis. Arch Pathol Lab Med 2004;128:195-204.
4. Lew TWK, Kwek T-K, Tai D, et al. Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome. JAMA 2003;290:374-380.
5. Who Mers-Cov Research Group. State of knowledge and data gaps of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in humans. PLoS Curr 2013; 5.
6. Sebag SC, Bastarache JA, Ware LB. Therapeutic modulation of coagulation and fibrinolysis in acute lung injury and the acute
respiratory distress syndrome. Curr Pharm Biotechnol. 2011; 12(9):1481-1496.

7. Ware LB, Bastarache JA, Wang L. Coagulation and fibrinolysis in human acute lung injury–new therapeutic targets? Keio J Med. 2005; 54:142-149.

8. Finigan JH. The coagulation system and pulmonary endothelial function in acute lung injury. Microvasc Res. 2009; 77:35-38.

9. Branchford BR, Carpenter SL. The role of inflammation in venous thromboembolism. Front Pediatr 2018; 6:142.

10. Saghazadeh A, Hafizi S, Rezaei N. Inflammation in venous thromboembolism: Cause or consequence? Int Immunopharmacol. 2015; 28:655-65.

11. Zeng F, Guo Y, Yin M, et al. Association of inflammatory markers with the severity of COVID-19. medRxiv BMJ Yale doi: https://doi.org/10.1101/2020.04.14.20065680

12. Tang N, Li D, Wang X, Sun Z, et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia, J Thromb Haemost. 2020;18:844-847.

13. Klok FA, Kruip MJHA, Vander Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. Apr 13, 2020. https://doi.org/10.1016/j.thromres.2020.04.013

14. Cui S, Chen S, Xiunan L, et al. Prevalence of venous thrombosis in patients with severe novel coronavirus pneumonia, doi:10: 1111/JTH:14830

15. Modigliani C, Iapichino G, Carenzo L. Venous and arterial thromboembolic complications and covid-19 patients admitted to an academic hospital in Milan, Italy. J Thromb https://doi.org/10: 1016/thrombosisresearch2020-04-024

16. The American Society of Hematology, Covid 19 and the TEE/ antiocoagulation frequently ask questions Baumann-Kreuziger et al.April 7, 2020 age https://www.hematology.org/Covid19

17. Thachil J, Tang N, Gando S, et al. International Society of Thrombosis and Hemostasis. Interim guidelines on recognition and management of Covid1 9 DOI: 10.1111/JTH :14810

18. Barnes G, Burnett A, et al. Thromboembolism and Hemostasis in acutely ill medical patients with asymptomatic proximal deep venous thrombosis or systemic venous thromboembolism: insights from the MAGELLAN trial. American Society of Hematology 2019. paper 0163

19. Kalayci Gibson CM, Chi G, et al. Asymptomatic deep venous thrombosis is associated with increased risk of death: insights from the APEX trial. Thromb Haemost. 2018 Dec;118(12):20462052.

20. Cohen A, Spiro T, Buller H, et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med. 2013; 368-5.

21. Cohen Harrington RA, Goldhaber SZ, et al. Extended thromboprophylaxis with betrixaban in acutely ill medical patients. N Engl J Med. 2016; 375:534-44

22. Spyropoulos AC, Ageno W, Albers G, et al. Rivaroxaban for thromboprophylaxis after hospitalization for medical illness. N Engl J Med 2018; 379:1118-1127

23. Goldhaber SZ Leizorovicz, KKAK AK, et al. Apixaban versus enoxaparin thromboprophylaxis in medically ill patients. N Engl J Med. 2011;365:2167-77

24. Weitz JI, Lensing AWA, Prins MH, et al. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med 2017; 376:1211-1222.

25. Agenelli G, Buller H, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013; 368: 699-708.

26. Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and antiphospholipid antibodies in patients with Covid 19. N Engl J Med. 2020. April 23, https://www.nejm.org/doi/full/10.1056/NEJMoa2007575

27. Akhter E, et al. IgG and IGA Beta2-GPI are associated with venous thrombosis in SLE Journal of rheumatology 2013;40: 2382-6

28. Dominguez V, Magder LS, Petri M. IgM anticardiolipin is not associated with lifetime rates of thrombotic events. Lupus Sci Med. 2016 Jun 20;3(1): e000107. doi: 10.1136/lupus -2015-000107.

29. Akhter E, et al. IgG and IGA Beta2-GPI are associated with venous thrombosis in patients with COVID-19. JACC. May 6, 2020.

30. Neumann I, Izcovich A, Zhang Y, et al. DOACS vs LMWH in hospitalized medical patients: a systemic review and meta-analysis that informed 2018 guidelines. Blood Advances. 2020; 14: 152-1517.

31. Raskob GE, Spyropoulos A, Spiro T, et al. Increased risk of death in acutely ill medical patients with asymptomatic proximal deep venous thrombosis or systemic venous thromboembolism: insights from the MAGELLAN trial. American Society of Hematology 2019. paper 0163

32. Lee W, Gardner R Porter T, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 2014; 124:188-195.

33. Parnanipe I, Fuster V, Laia, et al. An association with treatment dose anticoagulation with in-hospital survival among hospitalized patient with COVID-19. JACC. May 6, 2020.

34. The American Society of Hematology, Covid 19 and the TEE/ antiocoagulation frequently ask questions Baumann-Kreuziger et al.April 7, 2020 age https://www.hematology.org/Covid19

35. Thachil J, Tang N, Gando S, et al. International Society of Thrombosis and Hemostasis. Interim guidelines on recognition and management of Covid1 9 DOI: 10.1111/JTH :14810

36. Agnelli G, Buller H, et al. Apixaban versus enoxaparin thromboprophylaxis in medically ill patients. N Engl J Med. 2011;365:2167-77

37. Akhter E, et al. IgG and IGA Beta2-GPI are associated with venous thrombosis in SLE Journal of rheumatology 2013;40: 2382-6

38. Dominguez V, Magder LS, Petri M. IgM anticardiolipin is not associated with lifetime rates of thrombotic events. Lupus Sci Med. 2016 Jun 20;3(1): e000107. doi: 10.1136/lupus -2015-000107.

39. Akhter E, et al. IgG and IGA Beta2-GPI are associated with venous thrombosis in SLE Journal of rheumatology 2013;40: 2382-6

40. Bowles L, Platton S, Yartey N, et al. Lupus anticoagulant and antiphospholipid antibodies in patients with Covid 19. N Engl J Med. 2020. April 23, https://www.nejm.org/doi/full/10.1056/NEJMoa2007575

41. Frey NV, Porter DL. Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2016; 2016:567.
42. Xu XL, Han MF, Li TT, et al. Effective treatment of severe COVID-19 patients with tocilizumab. *PNAS*, 2020;117:20, 10970-75
43. Alattar R, Tawheed I, Shadid S, et al. Tocilizumab for treatment of severe coronavirus disease. *J Med Virol*. May 5, 2020 https://doi.org/10.1002/jmv.25964
44. Boulware DR, Pullen MF, Bangdiwala AS, et al. A Randomized trial of anticoagulation strategies in COVID-19. *NEJM*. 2020 Mar 20. doi: 10.1016/j.ijantimicag.2020.105949.
45. Schmidt-Tanguy A, Voswinkel J, Henrion D, et al. Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients. *J Thromb Haemost* 2013; 11: 1927-9.
46. Rand J.H, Wu X, Quinn A, et al. Hydroxychloroquine protects the AAA 5 anticoagulant shield from disruption by APL evidence for a novel effect for an old antimalarial drug, *Blood* 2010; 18; 115(11):2292-9.
47. Petri MA, Conklin J, O’Malley T, et al. Plateletbound C4d, low C3 and lupus anticoagulant associated with thrombosis in SLE., *Lupus Science & Medicine* 2019;6: e000318. doi:10.1136/lupus -2019-000318
48. Pierangeli S, Vega-Ostertag M, Harris E N, et al. A pathway to targeted therapies intracellular signaling triggered by antiphospholipid antibodies in platelets and endothelial cells. *J. Thromb Res* 2004;114(5-6):467–76
49. Magagnoli J, Narendran S, Pereira F, et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19, doi:https://doi.org/10.1101/2020.04.16.2006592051.
50. Geletis J, Sun Y, Platt J. Observational study of hydroxychloroquine in hospitalized patients with Covid-19 NEJMoa 082012410, . 2020 May 7;NEJMoa2012410.doi: 10.1056/NEJMoa2012410. Online ahead of print.N Engl J Med
51. Boulware DR, Pullen MF, Bangdiwala AS, et al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for COVID-19 [published online ahead of print, 2020 Jun 3]. *N Engl J Med*. 2020;NEJMoa2016638. doi:10.1056/NEJMoa2016638
52. Wang Y, Zhang D Guanhua D. Remdesivir in adults with severe Covid 19: A randomized double-blind placebo controlled multicenter trial Published Online April 29, 2020 https://doi.org/10 .1016/S0140-6736(20)31022-9.
53. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 - Preliminary Report [published online ahead of print, 2020 May 22]. *N Engl J Med*. 2020;NEJMoa2007764. doi:10.1056/NEJMoa2007764
54. Cao B, Wang Y, Wen D, et al. A trial of Lopinavir-ritonavir in adults hospitalized with severe Covid-19 . *N Engl J Med* 2020; 382: 1787-9
55. Shen C, Wang Z, Zhao F. Treatment of 5 critically ill patients with Covid 19 with convalescent plasma, doi:10.1001/jama.2020.4783 Published online March 27, 2020.
56. Duan K, Lui B, Li C, et al. Effectiveness of convalescent plasma treatment in severe COVID 19 patients *PNAS*- April 28, 2020.; 117 (17):9490-9496
57. Horby PW, Landray M, et al. Effect of dexamethasone in hospitalized patients with COVID-19—preliminary report. 22 Jun 2020(preprint). https://www.medrxiv.org/content/10.1101/2020 .06.22.20137273v1.full.pdf.
58. Trial evaluating efficacy and safety of anticoagulation in patients with COVID-19 infection, nested in the Corimmuno-19 Cohort (CORIMMUNO-COAG) ClinicalTrials.gov Identifier: NCT04344756.https://clinicaltrials.gov/ct2/show/NCT04344756
59. Preventing COVID-19 complications with low- and high-dose anticoagulation (COVID-HEP) ClinicalTrials.gov Identifier: NCT- 04345848.Iba, Thttps://clinicaltrials.gov/ct2/show/NCT04345848
60. A randomized trial of anticoagulation strategies in COVID-19 ClinicalTrials.gov Identifier: NCT04359277. https://clinicaltrials.gov/ct2/show/NCT04359277
61. Hematology recommendations and dosage guidelines. Covid 19, Massachusetts General Hospital version 8, April 30,2020
62. Considerations in the prophylaxis and treatment of venous thromboembolism and Covid 19 patients. Community of the American Venous Forum. Covid 19 @veinforum.com
63. Iba T, Levy J, Levi M, et al. Coagulopathy of Coronavirus Disease 2019. *Crit Care Med*. 2020;48(9):1358-1364.
64. Bikdeli B, Madhavan M, Jiminez D, et al. Covid 19 and thrombotic or thromboembolic disease: Implications for prevention, antithrombotic therapy and followup. https://doi.org/10.1016/j. jacc.2020.04.031
65. Kim KA, Park JY, Lee JS, et al. Cytochrome P450 2C8 and CYP3A4/5 are involved in chloroquine metabolism in human liver microsomes. *Arch Pharm Res*. 2003;26(8):631-637.
66. Chloroquine (All Populations Monograph) 3/17/2020 https://www.elsevier.com/data/assets/pdf_file/0008/990728/Chloro quine-Drug-.Monograph_3.17.2020.pdf (Accessed April 9, 2020)
67. Acedoyin A, Frye RF, Mauro K, et al. Chloroquine modulation of specific metabolizing enzymes activities: Investigation with selective five drug cocktail. *Br J Pharmacol*. 1998;46:215
68. Remdesivir - Summary on compassionate use. European Medicines Agency 03 April 2020 EMA/178637/2020 Human.\Medicines Division.
69. Actemra® [prescribing information]. Genentech, Inc., San Francisco, CA: 6/2019.